Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPIDIACAN

Financiado

Cerrado

Development of sensitive methodologies for exploitation of early epigenetic mark...

Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer Cancer is one of the major causes of mortality. Epithelial cells become malignant after accumulating genetic mutations followed by morphological changes in the epithelium. DNA Alterations include stable genetic changes in oncogene... ver más

31/12/2012

NATIONAL HELLENIC...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ETHNIKO IDRYMA EREVNON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-12-31 No tenemos la información de la convocatoria

0% 72% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

NATIONAL HELLENIC RESEARCH F...

0.00€ | Lider

UKLFR

N.D. | Participante

BIOMEDICALSCIENCES RESEARCH...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-08663 CARACTERIZACION EPIGENOMICA DE LAS NEOPLASIAS HEMATOLOGICAS 114K€ Cerrado

EVOEPIC Evolutionary mechanisms of epigenomic and chromosomal aberra... 1M€ Cerrado

RTI2018-094049-B-I00 DISRUPCION EPIGENETICA Y GENETICA DE LAS MODIFICACIONES DEL... Cerrado

CANCER EPIGENETICS Comprehensive characterization of epigentic reprogramming in... 100K€ Cerrado

MultiplexGenomics Exploring the Epigenome by Multiplexed Physical Mapping of I... 3M€ Cerrado

SAF2012-31138 METILACION DIFERENCIAL DEL ADN EN REGIONES NO PROMOTORAS: RE... 70K€ Cerrado

Líder del proyecto

ETHNIKO IDRYMA EREVNON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is one of the major causes of mortality. Epithelial cells become malignant after accumulating genetic mutations followed by morphological changes in the epithelium. DNA Alterations include stable genetic changes in oncogenes, tumor suppressor genes and reversible epigenetic changes. Different forms of epigenetic mechanisms have been shown to modify the expression of key genes during tumour progression. Promoter DNA hypermethylation of tumour suppressor genes or DNA repair genes, and covalent histone modifications appear in early stages of neoplasia. Methods to identify early markers in different types of cancer are being developed, although very few are specific and sensitive enough to be applied in the clinic. The aim of the present proposal is to develop sensitive and specific methodologies to identify early epigenetic markers for major types of cancer, like prostate and colorectal cancer. This project is based on recent findings that selected covalent histone modifications and their modifying enzymes can be early markers of tumourigenesis. For this purpose, the following will be applied. a) selected covalent histone modification like acetylation, methylation, phosphorylation, ubiquitination among others b) their modifying enzymes, like DNA (de)methylases and histone (de)acetylases, (de)methyltransferases c) appropriate diagnostic methods and tests for detection of selected markers in clinical samples. These markers are revealed from studies in cell and animal models as well from patient cohorts. Non-invasive diagnostic methods based on technologies developed in the participating organizations will be tested in clinical samples. Appropriately selected clinical samples will be utilized according to EU and national ethical procedures. The major task of this consortium will be the development of methods to be applied in the clinic for the immediate benefit of cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores